Last 28 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Nutex Health, Inc.'s quarterly P/E stands at 3.6x, down 20.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 33.9% YoY to 2.3x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 14.33 | 3.64 | 25.40 | 3.33 | — | 4.59 | 0.71 | — | — | — | — | — | — |
| — | -20.7% | +3465.7% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.02 | 0.79 | 1.95 | 0.69 | 0.75 | 0.32 | 0.16 | 0.35 | 0.10 | 0.25 | 0.41 | 0.54 | 1.17 |
| — | +142.4% | +1141.7% | +97.2% | +667.6% | +32.6% | -61.6% | -34.6% | -91.7% | -92.2% | -93.7% | -93.7% | -86.9% | |
| P/B Ratio | 2.40 | 1.27 | 2.79 | 1.69 | 2.16 | 1.00 | 0.80 | 1.39 | 0.36 | 0.83 | 1.44 | 1.28 | 2.56 |
| — | +26.7% | +248.6% | +22.0% | +499.4% | +21.2% | -44.4% | +8.0% | -85.9% | -87.1% | -87.6% | -82.5% | -30.5% | |
| P/FCF | 3.64 | 2.26 | 4.28 | 1.87 | 6.87 | 1.35 | — | 4.48 | 0.58 | 7.13 | — | — | — |
| — | +67.0% | — | -58.3% | +1079.6% | -81.0% | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.58 | 2.30 | 9.33 | 1.78 | 6.28 | 1.72 | 0.96 | 6.27 | 7.05 | 13.69 | — | 102.11 | 34.80 |
| — | +33.9% | +872.9% | -71.6% | -11.0% | -87.4% | — | -93.9% | -79.7% | — | — | — | -89.3% | |
| EV / EBIT | 3.85 | — | 10.89 | 1.86 | 8.31 | 1.93 | 1.01 | 32.76 | 7.74 | 17.97 | — | — | — |
| — | — | +980.4% | -94.3% | +7.3% | -89.3% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Nutex Health, Inc.'s operating margin was 37.5% in Q1 2026, up 17.2 pp QoQ and up 3.4 pp YoY. The trailing four-quarter average of 30.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 24.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 42.4% | 30.4% | 57.8% | 51.2% | 55.9% | 55.0% | 27.8% | 29.7% | 15.1% | 19.0% | 18.8% | 16.4% |
| — | -24.2% | -44.7% | +107.9% | +72.7% | +271.1% | +189.9% | +47.7% | +81.1% | +75.0% | +1821.4% | +122.6% | +43.2% | |
| Operating Margin | 31.5% | 37.5% | 20.4% | 48.7% | 13.8% | 34.1% | 44.3% | 12.3% | 7.0% | 2.1% | -37.5% | -1.3% | -0.6% |
| — | +10.1% | -54.0% | +297.0% | +98.2% | +1486.5% | +218.1% | +1036.6% | +1232.0% | +127.2% | -542.8% | +99.9% | +74.1% | |
| Net Margin | 8.1% | 21.6% | 7.8% | 20.7% | -7.3% | 6.9% | 23.9% | -11.2% | -0.5% | -0.5% | -45.4% | -8.8% | -5.9% |
| — | +212.9% | -67.4% | +285.6% | -1415.8% | +1380.3% | +152.8% | -26.2% | +91.9% | +94.1% | -451.5% | +99.4% | +82.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.6% | 9.7% | 2.7% | 14.3% | -5.8% | 6.1% | 43.8% | -10.9% | -0.4% | -0.5% | -34.4% | -5.2% | -3.2% |
| — | +58.6% | -93.7% | +231.7% | -1187.7% | +1441.5% | +227.5% | -108.9% | +85.9% | +89.8% | -882.8% | +95.6% | +47.1% | |
| ROA | 9.0% | 5.0% | 1.3% | 6.1% | -2.2% | 2.1% | 11.3% | -2.0% | -0.1% | -0.1% | -7.2% | -1.2% | -0.8% |
| — | +141.7% | -88.9% | +400.8% | -2406.4% | +2376.8% | +256.6% | -68.7% | +89.0% | +92.4% | -605.8% | +98.1% | +80.1% | |
| ROIC | 38.0% | 9.8% | 3.7% | 15.7% | 4.5% | 10.5% | 20.5% | 2.2% | 1.2% | 0.3% | -5.3% | -0.2% | -0.1% |
| — | -6.8% | -81.9% | +620.8% | +271.1% | +3069.0% | +486.6% | +1456.9% | +1716.3% | +135.4% | -652.6% | +99.7% | +69.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Nutex Health, Inc.'s Debt/EBITDA ratio is 3.7x, down from 9.7x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 38.2% YoY to 3.14x, strengthening the short-term liquidity position. Debt/Equity has declined for 7 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.60 | 0.83 | 0.89 | 1.02 | 1.24 | 1.69 | 3.80 | 3.52 | 3.40 | 3.49 | 3.12 | 2.65 |
| — | -51.4% | -50.8% | -76.6% | -70.9% | -63.5% | -51.6% | +21.7% | +32.7% | +32.3% | +57.0% | +58.3% | +507.5% | |
| Debt / EBITDA | 1.19 | 3.74 | 9.73 | 2.87 | 8.87 | 4.42 | 2.85 | 20.72 | 29.36 | 48.33 | — | 307.29 | 75.22 |
| — | -15.3% | +241.7% | -86.1% | -69.8% | -90.9% | — | -93.3% | -61.0% | — | — | — | -46.6% | |
| Current Ratio | 3.41 | 3.14 | 3.41 | 3.20 | 2.43 | 2.27 | 2.08 | 1.77 | 1.59 | 1.68 | 1.56 | 1.34 | 1.60 |
| — | +38.2% | +64.3% | +80.2% | +52.8% | +35.7% | +33.3% | +32.7% | -0.9% | -9.5% | -12.8% | -45.6% | -39.2% | |
| Quick Ratio | 3.39 | 3.12 | 3.39 | 3.18 | 2.42 | 2.26 | 2.06 | 1.74 | 1.55 | 1.63 | 1.50 | 1.30 | 1.56 |
| — | +38.2% | +65.1% | +82.7% | +55.8% | +38.8% | +37.1% | +34.3% | -0.6% | -8.6% | -12.9% | -45.6% | -39.7% | |
| Interest Coverage | 12.01 | 17.36 | 6.21 | 23.73 | 5.18 | 11.26 | 22.49 | 0.52 | 1.77 | 0.97 | -6.25 | -0.19 | -0.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUTX stock.
Nutex Health, Inc.'s current P/E is 14.3x. The average P/E over the last 3 quarters is 10.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nutex Health, Inc.'s current operating margin is 31.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nutex Health, Inc.'s business trajectory between earnings reports.